Guggenheim Capital’s Avidity Biosciences RNAM Stock Holding History

Guggenheim Capital’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-29,620	Closed	-$2.14M	–	1760
2025 Q4	$2.14M	Sell	29,620 -1,739	-6%	-$112K	0.02%	657
2025 Q3	$1.37M	Sell	31,359 -1,243	-4%	-$50.2K	0.01%	817
2025 Q2	$926K	Buy	32,602 +519	+2%	+$15.5K	0.01%	913
2025 Q1	$947K	Sell	32,083 -1,804	-5%	-$56.2K	0.01%	894
2024 Q4	$985K	Buy	33,887 +1,028	+3%	+$43K	0.01%	929
2024 Q3	$1.51M	Buy	+32,859	New	+$1.43M	0.01%	925

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Guggenheim Capital's RNAM Position: Q1 2026 in Review

Guggenheim Capital sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 29,620 shares — an estimated $2.14M sold.

Guggenheim Capital first reported a position in RNAM in Q3 2024 and held it in 6 quarters. The position peaked at $2.14M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Guggenheim Capital reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Guggenheim Capital sold 29,620 Avidity Biosciences shares in Q1 2026, an estimated $2.14M.
Guggenheim Capital first reported a position in Avidity Biosciences in Q3 2024 and held it in 6 quarters.
Guggenheim Capital's Avidity Biosciences position peaked at $2.14M in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.